fbpx

Intranasal booster trials get DCGI nod

  • IASbaba
  • January 29, 2022
  • 0
UPSC Articles
Print Friendly, PDF & Email

Intranasal booster trials get DCGI nod

Part of: Prelims and GS-II Health

Context: The Drugs Controller General of India (DCGI) has given vaccine manufacturer Bharat Biotech approval for conducting Phase 3 clinical trials of an intranasal booster dose for those who have received both doses of Covaxin.

  • The chimpanzee adenovirus vectored COVID-19 vaccine (BBV154) will be administered through an intranasal route, and each single dose is 0.5 ml.
  • Experts have noted that an intranasal vaccine as a booster will be easier to administer in mass vaccination drives. 
  • By reducing the need for needles and syringes, among others, such vaccines would also impact the overall cost of a vaccination drive.

Nasal vaccine

  • A nasal vaccine is a vaccine administered to a person via the nose and does not require a needle. 
  • It induces immunity through the inner surface of the nose, a surface that naturally comes in contact with many airborne microbes

About Drugs Controller General of India 

  • He is the head of department of the Central Drugs Standard Control Organization of the Government of India.
    • Central Drugs Standard Control Organisation works in close collaboration with the state control administration and assist them in securing uniform enforcement of the Drug Act.
  • Responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids, vaccines, and sera in India.
  • DCGI also sets standards for manufacturing, sales, import, and distribution of drugs in India.
  • Comes under the Ministry of Health & Family Welfare.

News Source: TH

For a dedicated peer group, Motivation & Quick updates, Join our official telegram channel – https://t.me/IASbabaOfficialAccount

Subscribe to our YouTube Channel HERE to watch Explainer Videos, Strategy Sessions, Toppers Talks & many more…

Search now.....